November 14, 2018 — On Tuesday in Nashville, Steven Nissen delivered the opening keynote lecture. From beginning to end, he told us, obesity is all about the heart. “Heart disease is how obesity kills most of our patients,” he said. “It is still the leading cause of death, and we’re going to have to tackle this.” Halting Progress Against Heart […]
July 18, 2018 — For the first time ever, we have direct evidence for the long-term cardiovascular safety of an obesity medication. The drug is Belviq, also known as lorcaserin. Yesterday, Eisai released topline results for the long-awaited CAMILLIA-TIMI 61 trial. This was a five-year cardiovascular outcomes study of 12,000 patients. It was randomized and placebo controlled. CV Safety […]
March 7, 2016 — A major new study shows that people treated with liraglutide for type 2 diabetes have fewer strokes, heart attacks, and deaths from heart disease. Six years ago, cardiovascular outcomes had doctors scratching their heads about diabetes and obesity drugs. A hearing on a flawed outcome study with sibutramine resulted in its withdrawal from the market. […]
November 10, 2015 — If you thought that the onslaught of new studies was done with the closing of ObesityWeek on Friday, think again. Now we have two important new studies of liraglutide and heart disease that were presented at the Annual Scientific Sessions of the American Heart Association (AHA) on Sunday and Monday. The study that’s hogging all the […]
May 14, 2015 — Investment in obesity research and development is a scarce resource. There’s no supply of money to burn. So the news of the termination of a large, expensive cardiovascular outcomes trial of naltrexone/bupropion (Contrave) is sad news indeed. This was the inevitable result of a mistake involving premature release of interim data from this study. As […]
